Approval · Notice of Compliance 32016 · 2023
MENQUADFI: Notice of Compliance 32016
Issued November 2, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 32016
- Date
- November 2, 2023
- Company
- Sanofi Pasteur LimitedSwiftwater, Pennsylvania, United States
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Labelling Only
- Reason
- Update to labelling
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| MENQUADFI | Not yet assigned | — |
Medicinal ingredients
- MENINGOCOCCAL GROUP A POLYSACCHARIDE-TETANUS TOXOID CONJUGATE 10 MCG per 0.5ML
- MENINGOCOCCAL GROUP C POLYSACCHARIDE-TETANUS TOXOID CONJUGATE 10 MCG per 0.5ML
- MENINGOCOCCAL GROUP W POLYSACCHARIDE-TETANUS TOXOID CONJUGATE 10 MCG per 0.5ML
- MENINGOCOCCAL GROUP Y POLYSACCHARIDE-TETANUS TOXOID CONJUGATE 10 MCG per 0.5ML